Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer

ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license…

Read More

Wugen Announces the Appointment of Company’s Co-founder, Matt Cooper, Ph.D., as Chief Scientific Officer

ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s co-founder, Matt Cooper, Ph.D., as…

Read More

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement…

Read More

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s…

Read More

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…

Read More